Combination therapy with candesartan cilexetil 32mg and hydrochlorothiazide 25mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care

Clinical Drug Investigation

Volumn 29, Issue 5, 2009, Pages 293-304

  Edes, Istvan ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN HEXETIL; HYDROCHLOROTHIAZIDE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTPATIENT; PARALLEL DESIGN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; TETRAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65349088977     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200929050-00002     Document Type: Article

References (23)

1. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362 (9395): 1527-35
2. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999 Feb; 17 (2): 151-83
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25 (6): 1105-87
4. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003 May 21; 289 (19): 2560-72
5. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998 Jun 13; 351 (9118): 1755-62
6. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62 (8): 1253-87
7. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Am J Hypertens 1999 Dec; 12 (12 Pt 1-2): 1181-7
8. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers: differences in potency and efficacy. Blood Pressure 2002; 11 (5): 293-301
9. Ramsay LE, Yeo WW, Chadwick IG, et al. Diuretics. In: Swales JD, editor. Textbook of hypertension. Oxford: Blackwell Scientific Publications, 1994
10. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med 1996 Sep 30; 101 Suppl. 3A: 71-82
11. Philipp T, Letzel H, Arens H-J. Dose-finding study of can-desartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 1997 Sep; (11 Suppl.) 2: 67-8
12. Papademetriou V, Reif M, Henry D, et al. Combination therapy with candesartan cilexetil and hydrochlorothiazide in patients with systemic hypertension. J Clin Hypertens 2000 Nov/Dec; 2 (6): 372-8
13. Melian EB, Jarvis B. Candesartan cilexetil plus hydro-chlorothiazide combination: a review of its use in hypertension. Drugs 2002; 62 (5): 787-816
14. Brewster LW, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004 Oct 19; 141 (8): 614-27
15. Bonner G, for the Multicentre Study Group. Anti-hypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5mg and 32/25mg in patients not optimally controlled with candesartan monotherapy. Blood Pressure 2008; 17 Suppl. 2: 22-30
16. Wagstaff AJ. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs 2006; 66 (14): 1881-01
17. Fenton C, Keating GM, Scott LJ. Telmisartan/hydrochlorothiazide in the treatment of essential hypertension. Drugs 2003; 63 (19): 2013-26
18. Neutel JM, Franklin SS, Lapuerta P, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2008 Apr; 22 (4): 266-74
19. Gradman AH, Brady WE, Gazdick LP, et al. A multicentre, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100mg/hydrochlorothiazide 25mg and losartan 50mg/ hydrochlorothiazide 12.5mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002 Jul; 24 (7): 1049-61
20. Bakris G,GradmanA, Reif M, etal. Antihypertensive efficacy of candesartanin comparison tolosartan: the CLAIM study. J Clin Hypertens (Greenwich) 2001 Jan-Feb; 3 (1): 16-21
21. Vidt DG, White WB, Ridley E, et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM study II. J Hum Hypertens 2001 Jul; 15 (7): 475-80
22. Öhman KP, Milon H, Valnes K. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydro-chlorothiazide in insufficiently controlled primary hypertension: comparison with a combination of losartan and hydrochlorothiazide. Blood Pressure 2000; 9 (4): 214-20
23. Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension: results of the CARLOS-study. Clin Drug Invest 2000 April; 19 (4): 239-46